Tillman Gerngross, Ph.D., is a Professor of Bioengineering at Dartmouth College and an active entrepreneur and innovator. He has founded several highly successful companies including GlycoFi, where he lead the effort to humanize the glycosylation machinery in yeast to produce fully human glycoproteins. Since 2006, Gerngross has served as a Venture Partner at SV Life Science and in 2007 he co-founded Adimab, which since has launched one of the most commercially successful antibody discovery technologies in the last few decades. In 2010 Adimab was awarded the Technology Pioneer award by the World Economic Forum in Davos. In 2010 Gerngross also co-founded Arsanis Inc. to develop antibody based therapies for the treatment of infectious diseases. In 2012 Gerngross co-founded Avitide to address a bottleneck in the purification of protein based therapeutics and in 2013 Gerngross co-founded Alector to develop new treatment strategies for dementia and Alzheimers related diseases. Since 2013 Gerngross has also served as the Associate Provost of Entrepreneurship and Technology Transfer at Dartmouth College.